Zimmer Biomet announced that the U.S. Department of Justice and Securities and Exchange Commission continue to evaluate the company’s past conduct in Brazil and Mexico, regarding possible violations of the Foreign Corrupt Practices Act.
As noted in the company’s recent 8-K filing,
“The DOJ, the SEC and Biomet have agreed to continue to evaluate and discuss these matters during the second quarter of 2016 and, therefore, the matter is ongoing and will not conclude in its entirety on March 26, 2016.”
Biomet entered into a 3-year Deferred Prosecution Agreement (DPA) with the U.S. DOJ and a Consent to Final Judgment with the U.S. SEC in 2012. In 1Q15, the company disclosed that the DPA and independent compliance monitor were extended for an additional year.
Zimmer Biomet announced that the U.S. Department of Justice and Securities and Exchange Commission continue to evaluate the company's past conduct in Brazil and Mexico, regarding possible violations of the Foreign Corrupt Practices Act.
As noted in the company's recent 8-K filing, "The DOJ, the SEC and Biomet have agreed to continue to...
Zimmer Biomet announced that the U.S. Department of Justice and Securities and Exchange Commission continue to evaluate the company’s past conduct in Brazil and Mexico, regarding possible violations of the Foreign Corrupt Practices Act.
As noted in the company’s recent 8-K filing,
“The DOJ, the SEC and Biomet have agreed to continue to evaluate and discuss these matters during the second quarter of 2016 and, therefore, the matter is ongoing and will not conclude in its entirety on March 26, 2016.”
Biomet entered into a 3-year Deferred Prosecution Agreement (DPA) with the U.S. DOJ and a Consent to Final Judgment with the U.S. SEC in 2012. In 1Q15, the company disclosed that the DPA and independent compliance monitor were extended for an additional year.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
